A Phase 1 interventional study of VP-001 in Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy and RP11, sponsored by PYC Therapeutics. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by PYC Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Retinal Dystrophies with a site in United States — 8 open to participants now, 16 under way, none of them phase 3. Retinal Dystrophies · United States.
Among the 27 studies in Retinal Dystrophies with a site in United States, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2023, is one of 4 in phase 1, and was the 17th registered.
60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.
Browse Retinal Dystrophies studies →8 of the 27 studies in Retinal Dystrophies with a site in United States are open now. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in United States, Australia, China
Ages 18–65
University of Rochester · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8
First in 1994; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is close to the median of 18 across 34 interventional studies indexed under Retinal Dystrophies.
Median enrollment 20 across the 16 interventional studies, 35 across the 11 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 27 have an industry lead sponsor. The 10 most frequent:
PYC Therapeutics is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
PYC Therapeutics has 4 studies filed under Retinal Dystrophies — fewer than ten, so there is no comparison to draw.
8 of the studies in Retinal Dystrophies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05294978Institute of Molecular and Clinical Ophthalmology BaselEyeConic: Qualification for Cone-Optogenetics | 2026-12 |
| NCT05748873SparingVisionPromising ROd-cone DYstrophy Gene therapY | 2027-02 |
| NCT07502664Ray Therapeutics, Inc.Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD) | 2027-02 |
| NCT05626920University of WashingtonDisulfiram for Treatment of Retinal Degeneration | 2027-02-01 |
| NCT06048185Nanoscope Therapeutics Inc.Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 27 studies in Retinal Dystrophies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
6. Have light perception (LP) or better vision in the study eye. 7. Participants of and male participants must not be pregnant or lactating and must be sexually inactive by abstinence, which is consistent with the preferred and usual lifestyle of the participant or agree to use adequate throughout study duration. Adequate birth control is defined as hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine device (IUD); or surgical sterilization of partner. For nonsexually active participants, abstinence may be regarded as an adequate method of birth control. Participants of childbearing potential include all participants who have experienced menarche and have not undergone successful surgical sterilization (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) or are not (12 months after last menses).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: VP-001
Phase 1 open-label, single arm dose escalation study of VP-001 in participants with genetically confirmed PRPF31 mutation-associated retinal dystrophy
The incidence, severity, and relatedness of treatment-emergent ocular adverse events (TEAEs) and treatment-emergent serious adverse events (TE-SAEs) in the study eye
Time frame: over a 24-week time period
The incidence, severity, and relatedness of treatment-emergent ocular adverse events (TEAEs) and treatment-emergent serious adverse events (TE-SAEs) in the study eye
Time frame: over a 48-week time period
Adverse Events and Treatment Emergent Serious adverse events (SAEs) in the fellow eye
Time frame: over a 24-week time period
Adverse Events and Treatment Emergent serious adverse events (SAEs) in the fellow eye
Time frame: over a 48-week time period
Incidence, severity relatedness and of non-ocular TEAEs
Time frame: over a 24-week time period
Incidence, severity relatedness and of non-ocular TEAEs
Time frame: over a 48-week time period
Change from Baseline in Best-corrected visual acuity (BCVA) letter score using Early Treatment Diabetic Retinopathy Study (ETDRS) charts
Time frame: over a 24-week time period
Change from Baseline in Best-corrected visual acuity (BCVA) letter score using Early Treatment Diabetic Retinopathy Study (ETDRS) charts
Time frame: over a 48-week time period
Change from Baseline in lowest passing light level using Ora-VNC™ mobility test
Time frame: over a 24-week time period
Change from Baseline in lowest passing light level using Ora-VNC™ mobility test
Time frame: over a 48-week time period
Change from Baseline in Low luminance visual acuity (LLVA) letter score
Time frame: over a 24-week time period
Change from Baseline in Low luminance visual acuity (LLVA) letter score
Time frame: over a 48-week time period
Change from Baseline in Visual field sensitivity as measured by static perimetry with topographic analysis (Hill of Vision)
Time frame: over a 24-week time period
Change from Baseline in Visual field sensitivity as measured by static perimetry with topographic analysis (Hill of Vision)
Time frame: over a 48-week time period
Change from Baseline in Mean retinal sensitivity as measured by fundus-guided microperimetry
Time frame: over a 24-week time period
Change from Baseline in Mean retinal sensitivity as measured by fundus-guided microperimetry
Time frame: over a 48-week time period
Change from Baseline in Visual fields as measured by kinetic perimetry, utilizing I4e, III4e and V4e stimuli
Time frame: over a 24-week time period
Change from Baseline in Visual fields as measured by kinetic perimetry, utilizing I4e, III4e and V4e stimuli
Time frame: over a 48-week time period
Change from Baseline in Rod- and cone-mediated retinal function as measured by white, red and blue FST
Time frame: over a 24-week time period
Change from Baseline in Rod- and cone-mediated retinal function as measured by white, red and blue FST
Time frame: over a 48-week time period
Change from Baseline in Retinal thickness on SD-OCT, including retinal thickness in each ETDRS subfield and ellipsoid zone (EZ) area and volume
Time frame: over a 24-week time period
Change from Baseline in Retinal thickness on SD-OCT, including retinal thickness in each ETDRS subfield and ellipsoid zone (EZ) area and volume
Time frame: over a 48-week time period
Change from Baseline in Participant reported outcome measures utilizing the Patient Global Impressions of Change (PGI-C) and Patient Global Impressions of Severity (PGI-S)
Time frame: over a 24-week time period
Change from Baseline in Participant reported outcome measures utilizing the Patient Global Impressions of Change (PGI-C) and Patient Global Impressions of Severity (PGI-S)
Time frame: over a 48-week time period
Change from Baseline in Retinal function using full-field electroretinography (ERG)
Time frame: over a 24-week time period
Change from Baseline in Retinal function using full-field electroretinography (ERG)
Time frame: over a 48-week time period
Change from Baseline in Area of hypo-autofluorescence captured by FAF
Time frame: over a 24-week time period
Change from Baseline in Area of hypo-autofluorescence captured by FAF
Time frame: over a 48-week time period
Change from Baseline in Abnormalities captured by wide-field fundus photography
Time frame: over a 24-week time period
Change from Baseline in Abnormalities captured by wide-field fundus photography
Time frame: over a 48-week time period
Ran from Apr 2023 to primary completion in Aug 2025, 27 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VP-001
PYC Therapeutics